ArriVent BioPharma

ArriVent BioPharma

AVBP· Manufacturing· Fiscal year ends in December

CEO pay in FY2025Stock -24.5% in FY2025

Zhengbin (Bing) Yao, Ph.D is the CEO of ArriVent BioPharma and was paid $9.4M in FY2025 (Dec), up 290%.

Pay$100 in the stock at the end of FY24 → $76
CEO pay is from each ArriVent BioPharma proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Executives3

See all
  1. 1Zhengbin (Bing) Yao, Ph.DFY2025
  2. 2Stuart Lutzker, M.D., Ph.DFY2025
  3. 3Winston Kung, MBAFY2025

Named executives and their total pay, from the Summary Compensation Table of the latest proxy.

Pay

See all

ArriVent BioPharma paid its 3 named executives $16.2M in total in FY2025 (Dec). CEO Zhengbin (Bing) Yao, Ph.D was paid $9.4M of that.

Name
Zhengbin (Bing) Yao, Ph.DChief Executive Officer and President
Stuart Lutzker, M.D., Ph.DPresident, Research and Development
Winston Kung, MBAChief Financial Officer and Treasurer

of each named executive, from the Summary Compensation Table of each proxy.

Peers

No disclosed peer group

No proxy on file names a pay peer group for ArriVent BioPharma. The peer group comes from the proxy statement, so it shows here when a proxy read has it.

Board1

See all
  • Kristine PetersonLead independent director · 1 yr on the boardIndependentAudit, Compensation (Chair)—Paid as an executive

The board of the latest proxy (FY2025).

Activity

Filings5

See all
Proxy statementDEF 14AApr 28, 2026FY2025
Annual report10-KMar 5, 2026FY2025
Proxy statementDEF 14AApr 28, 2025FY2024
Annual report10-KMar 3, 2025FY2024
Annual report10-KMar 28, 2024FY2023
For the press:Download CSVDownload PNGHow to use our data